On February 26, 2021 Sprint Bioscience AB (publ) reported that Erik Kinnman has been appointed new CEO of the company (Press release, Sprint Bioscience, FEB 26, 2021, View Source [SID1234575736]). He has 25 years of experience from leading positions in the pharmaceutical and biotechnology industry. Erik Kinnman will take up the role on March 1 and succeed Charlotte Leife, who has been acting CEO since September 1, 2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Erik Kinnman was between 2016 and January 2021 CEO of Abliva AB (formerly Neurovive), a biotechnology company listed on Nasdaq Stockholm’s Main Market. Prior to that, he held senior positions at AstraZeneca and SOBI and was also active as a financial analyst at Danske Bank. Erik Kinnman is a physician, Doctor of Medicine, and associate professor at Karolinska Institutet. He has a specialist education in neurology and pain relief, as well as an Executive MBA from the Stockholm School of Economics.
"We are very pleased to welcome Erik Kinnman as the new CEO of Sprint Bioscience. His extensive experience from leading positions in global pharmaceutical companies, solid scientific background, and thorough understanding of the capital market give him excellent qualifications to lead the company in its further development. I would also like to extend a big thank you to Charlotte Leife for her significant efforts during her time as Acting CEO", says Sprint Biosciences’ Chairman of the Board, Rune Nordlander.
"I see great potential in Sprint Bioscience’s unique pharmaceutical project and business model, and I look forward to leading a company where employees have such strong competence and innovative power. My focus will be on optimizing the potential for current partner projects to succeed and for more collaboration agreements with international pharmaceutical companies to be concluded, as well as to ensure resource-efficient generation of new pharmaceutical projects to create significant shareholder value", says Erik Kinnman, incoming CEO of Sprint Bioscience.